Ray F Ebert

US Patent:

58559191, Jan 5, 1999

Filed:

Mar 26, 1997

Appl. No.:

8/837498

Inventors:

Ray F. Ebert - Derwood MD
Richard D. Swerdlow - Silver Spring MD

Assignee:

PerImmune Holdings, Inc. - Rockville MD

International Classification:

A61K 3556

US Classification:

424547

Abstract:

The present intention is directed to a stabilized keyhole limpet hemocyanin (KLH) composition in which (i) its intact non-degraded subunit is approximately 400,000 in molecular weight based on SDS-PAGE analysis; and (ii) are contained at least about 50% didecameric or higher KLH multimers, based on sedimentation-equilibrium and/or sedimentation-velocity ultracentrifugation analyses. The KLH composition is stabilized at 4. degree. C. by dissolving and storing it in an isotonic buffer preferably containing calcium and magnesium. It is critical that the KLH not have been frozen or lyophilized during its preparation or storage. The KLH composition demonstrates enhanced immunogenic activity, particularly enhanced anti-tumor activity, which is reduced if the KLH is frozen or lyophilized. The KLH composition of the present invention exhibits enhanced anti-tumor activity in a murine bladder tumor model and thereby represents a new and useful anti-tumor immunotherapeutic agent.

US Patent:

54139198, May 9, 1995

Filed:

Jun 21, 1994

Appl. No.:

8/263410

Inventors:

Ray F. Ebert - Derwood MD
Rafael P. Valdes-Camin - Germantown MD

Assignee:

Akzo N.V. - Arnhem

International Classification:

C12P 2102
C12P 100
C12Q 156

US Classification:

435 703

Abstract:

A method for preparing a thromboplastin reagent from cultured human cells comprising the steps of washing the cells with isotonic aqueous salt solution, lysing the cells by hypotonic shock, and resuspending the cell lysate in a diluent compatible with a one-stage prothrombin time determination to reach a concentration of about 0. 5 to 3. 0 mg/mL thromboplastin, whereby the cell lysate thromboplastin suspension produces a clot in a one stage prothrombin time test in about 10 to 15 seconds, with a mean normal prothrombin time of about 11-13 seconds, when added to citrated normal plasma in a volume ratio of about 2:1, such thromboplastin reagent being stable for at least 8 hours at 37. degree. C. and for at least 5 days at 4. degree. C.

US Patent:

59814764, Nov 9, 1999

Filed:

Jan 20, 1998

Appl. No.:

9/009121

Inventors:

Ray F. Ebert - Derwood MD
Richard D. Swerdlow - Silver Spring MD

Assignee:

Perimmune Holdings, Inc. - Rockville MD

International Classification:

A61K 3816

US Classification:

514 8

Abstract:

The present invention is directed to a stabilized keyhole limpet hemocyanin (KLH) composition in which (i) its intact non-degraded subunit is approximately 400,000 in molecular weight based on SDS-PAGE analysis; and (ii) are contained at least about 50% didecameric or higher KLH multimers, based on sedimentation-equilibrium and/or sedimentation-velocity ultracentrifugation analyses. The KLH composition is stabilized at 4. degree. C. by dissolving and storing it in an isotonic buffer preferably containing calcium and magnesium. It is critical that the KLH not have been frozen or lyophilized during its preparation or storage. The KLH composition demonstrates enhanced immunogenic activity, particularly enhanced anti-tumor activity, which is reduced if the KLH is frozen or lyophilized. The KLH composition of the present invention exhibits enhanced anti-tumor activity in a murine bladder tumor model and thereby represents a new and useful anti-tumor immunotherapeutic agent.

US Patent:

54079128, Apr 18, 1995

Filed:

Apr 19, 1993

Appl. No.:

8/050697

Inventors:

Ray F. Ebert - Derwood MD
Richard D. Swerdlow - Silver Spring MD

Assignee:

Akzo, N.V. - Arnhem

International Classification:

A61K 3710

US Classification:

514 8

Abstract:

The present invention is directed to a stabilized keyhole limpet hemocyanin (KLH) composition in which (i) its intact non-degraded subunit is approximately 400,000 in molecular weight based on SDS-PAGE analysis; and (ii) are contained at least about 50% didecameric or higher KLH multimers, based on sedimentation-equilibrium and/or sedimentation-velocity ultracentrifugation analyses. The KLH composition is stabilized at 4. degree. C. by dissolving and storing it in an isotonic buffer preferably containing calcium and magnesium. It is critical that the KLH not have been frozen or lyophilized during its preparation or storage. The KLH composition demonstrates enhanced immunogenic activity, particularly enhanced anti-tumor activity, which is reduced if the KLH is frozen or lyophilized. The KLH composition of the present invention exhibits enhanced anti-tumor activity in a murine bladder tumor model and thereby represents a new and useful anti-tumor immunotherapeutic agent.